# Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

> **NCT04874194** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Recurrent Acute Biphenotypic Leukemia
- Recurrent Acute Myeloid Leukemia
- Recurrent Myelodysplastic Syndrome
- Refractory Acute Biphenotypic Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory Myelodysplastic Syndrome

## Interventions

- **DRUG:** Omacetaxine Mepesuccinate
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04874194
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-17
- **Primary completion:** 2024-09-16
- **Final completion:** 2024-09-16
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** The study terminated early because the company was longer providing the investigational product.
- **Last updated:** 2025-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04874194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04874194, "Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04874194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*